Piscitelli Dominic 4

4 · Oric Pharmaceuticals, Inc. · Filed Dec 17, 2025

Form 4

Period: 2025-12-15

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2025-12-15+29,333→ 78,868 total
Sale
Common Stock
2025-12-16$9.06/sh−10,720$97,127→ 68,148 total
Exercise/Conversion
Restricted Stock Unit
2025-12-15−8,000→ 0 total
→ Common Stock (8,000 underlying)
Exercise/Conversion
Restricted Stock Unit
2025-12-15−10,000→ 10,000 total
→ Common Stock (10,000 underlying)
Exercise/Conversion
Restricted Stock Unit
2025-12-15−11,333→ 22,667 total
→ Common Stock (11,333 underlying)

Footnotes (7)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
[F2]Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
[F3]Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
[F4]Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
[F6]1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
[F7]1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

Documents

1 file